PUBLISHER: DelveInsight Business Research LLP | PRODUCT CODE: 1069355
PUBLISHER: DelveInsight Business Research LLP | PRODUCT CODE: 1069355
DelveInsight's, "Chemotherapy Induced Anemia- Pipeline Insight, 2022," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Chemotherapy Induced Anemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Chemotherapy-induced anemia (CIA) is a consequence of malignant invasion of normal tissue leading to blood loss, bone marrow infiltration with disruption of erythropoiesis, and functional iron deficiency as a consequence of inflammation. CIA is a significant consequence of chemotherapy and may delay or limit therapy as well as contribute to both fatigue and diminished quality of life. Chemotherapy-induced anemia (CIA) is a multifaceted entity influenced by a variety of patient- and treatment-specific factors. Some sources of variation within CIA include chemotherapeutic agent as well as dose and administration schedule, type and stage of malignancy, baseline pretreatment hemoglobin, target hemoglobin, timing of intervention (red blood cell transfusion, iron, erythropoietin stimulating agent), nutritional status, renal function, age, and gender. The diversity of patient presentation and symptomatology within the broader spectrum of CIA contributes to the challenge of establishing universal criteria to govern optimal management therapies. This manuscript will review the development and evolution of CIA with an emphasis on assorted therapeutic interventions. CIA is most frequently observed in hematologic, particularly myeloid, malignancies more so than in solid tumors. The two primary objectives of CIA treatment are to alleviate symptoms and to improve quality of life. Failing to treat CIA may contribute to a suboptimal response to the Current practices to treat CIA include packed red blood cell transfusions, erythropoietin stimulating agents (ESAs), and iron supplementation and correction of anemia in patients is correlated with improved responses to chemotherapy.
"Chemotherapy Induced Anemia- Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chemotherapy Induced Anemia pipeline landscape is provided which includes the disease overview and Chemotherapy Induced Anemia treatment guidelines. The assessment part of the report embraces, in depth Chemotherapy Induced Anemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chemotherapy Induced Anemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Chemotherapy Induced Anemia R&D. The therapies under development are focused on novel approaches to treat/improve Chemotherapy Induced Anemia.
This segment of the Chemotherapy Induced Anemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Roxadustat, a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, promotes coordinated erythropoiesis through increasing endogenous erythropoietin, improving iron availability, and reducing hepcidin. Administration of roxadustat has been shown to increase red blood cell production while maintaining plasma erythropoietin levels within or near normal physiologic range in multiple subpopulations of CKD patients, including in the presence of inflammation, and without a need for supplemental intravenous iron. Roxadustat is currently approved in China, Japan, Europe, Chile, and South Korea for the treatment of anemia in CKD patients on dialysis and patients not on dialysis. The U.S. Food and Drug Administration issued a complete response letter for the roxadustat NDA filing for the treatment of CKD anemia in August 2021. Roxadustat is in Phase 3 clinical development in the U.S., Europe, and China for anemia associated with myelodysplastic syndromes (MDS), and in a Phase 2 U.S. trial for treatment of chemotherapy-induced anemia (CIA).
SBI Pharmaceuticals Co., which researches and develops pharmaceuticals, health foods, and cosmetics using 5-aminolevulinic acid (5-ALA) has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) to conduct a phase-1 clinical trial on a formulation including 5-ALA for treating anemia caused by cancer chemotherapy. Formulations including 5-ALA are expected to improve symptoms of anemia by activating the hematopoietic capability. 5-aminolevulinic acid (5-ALA): An amino acid created in mitochondria. It is an important substance that serves as protein material related to energy production in the form of hemes and cytochromes, and its productivity is known to decrease with age. 5-ALA is contained in shochu distillation remnants, red wine and food such as radish sprouts. It is also known as a material forming chloroplasts in plants.
This segment of the report provides insights about the different Chemotherapy Induced Anemia drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 3+ key companies which are developing the therapies for Chemotherapy Induced Anemia. The companies which have their Chemotherapy Induced Anemia drug candidates in the most advanced stage, i.e. phase II include, FibroGen.
DelveInsight's report covers around 3+ products under different phases of clinical development like:
Chemotherapy Induced Anemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chemotherapy Induced Anemia therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chemotherapy Induced Anemia drugs.